指南与共识免疫规划传染病防控与疫情报告妇幼与学校卫生

2018年日本冲绳大规模麻疹暴发期间6-11月龄婴儿紧急含麻疹疫苗接种建议及疫苗相关麻疹检测

Emergent measles-containing vaccination recommendation for aged 6-11 months and detection of vaccine-associated measles during a large measles outbreak in Okinawa, Japan, in 2018.
指南 / 共识 · Vaccine · 2020-02-06

2018年3-5月日本冲绳发生大规模麻疹暴发, laboratory-confirmed 99例,疫苗相关麻疹14例。冲绳县政府为6-11月龄婴儿引入紧急含麻疹疫苗接种建议。8062名婴儿接种MCV,6例发生疫苗相关麻疹,发病率0.74/1000剂(95%CI 0.27-1.62),与1岁常规首剂接种者(IR 0.60,95%CI 0.20-1.78)相似。14例疫苗相关麻疹中,咽拭子RT-qPCR阳性率最高(92.9%),其次为尿(25.0%)和全血(7.7%)。本次暴发无婴儿死亡,6-11月龄婴儿接种MCV后未见严重免疫接种不良事件。作者认为引入紧急MCV有效,描述疫苗相关麻疹病例特征有助于未来暴发应对。

要点

  • 冲绳2018年麻疹暴发期间实验室确诊99例,疫苗相关麻疹14例。
  • 6-11月龄婴儿接种MCV后疫苗相关麻疹发病率0.74/1000剂(95%CI 0.27-1.62)。
  • 疫苗相关麻疹咽拭子RT-qPCR阳性率最高(92.9%),其次尿(25.0%)、全血(7.7%)。

核心结论

  • 作者认为引入紧急MCV有效,描述疫苗相关麻疹病例特征有助于未来暴发应对。

研究设计与样本

  • 指南类:冲绳县政府在2018年3-5月麻疹暴发期间引入6-11月龄婴儿紧急含麻疹疫苗接种建议,并检测疫苗相关麻疹病例。

主要发现

  • 2018年3-5月冲绳麻疹暴发期间实验室确诊99例,疫苗相关麻疹14例。
  • 8062名6-11月龄婴儿接种MCV,6例发生疫苗相关麻疹,发病率0.74/1000剂(95%CI 0.27-1.62)。
  • 1岁常规首剂接种者疫苗相关麻疹IR 0.60(95%CI 0.20-1.78)。
  • 14例疫苗相关麻疹中,咽拭子RT-qPCR阳性率92.9%,尿25.0%,全血7.7%。
  • 1例RT-qPCR判定为不确定的咽拭子样本经传统RT-PCR检测为阳性。

关键数值与推荐

  • 冲绳县政府为6-11月龄婴儿引入紧急含麻疹疫苗接种建议。
  • 本次暴发无婴儿死亡,6-11月龄婴儿接种MCV后未见严重免疫接种不良事件。

临床怎么用

  • 暴发期间应尽可能准确、紧急地区分野生循环病毒引起的麻疹样症状病例与疫苗衍生病毒引起的病例,因公共卫生应对措施不同。
  • 作者认为引入紧急MCV有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Okinawa Prefecture, Japan, experienced a large measles outbreak from March to May 2018. During this outbreak, there were 99 laboratory-confirmed cases and 14 vaccine-associated measles cases. In addition to the reinforcement of routine immunization, Okinawa prefectural government introduced emergent measles-containing vaccination recommendations for infants aged 6-11 months as part of the outbreak response. Increased concern exists in Okinawa about measles in infants following a previous outbreak from 1998 to 2001, when nine children including four infants died. Of 8062 infants aged 6-11 months who received measles-containing vaccine (MCV), six developed vaccine-associated measles; incidence was 0.74 per 1000 doses (95%CI 0.27-1.62). This was similar to that of first dose routine immunization recipients at one year of age (IR 0.60, 95%CI 0.20-1.78). Among 14 vaccine-associated measles cases, throat swab samples showed the highest positive rate (92.9%) by real-time reverse transcription polymerase chain reaction (RT-qPCR), followed by urine (25.0%) and whole blood (7.7%) samples. Furthermore, one throat swab sample classified as equivocal by RT-qPCR was positive by conventional RT-PCR (RT-PCR). During an outbreak, it is critical to distinguish between cases with measles-like symptoms caused by wild circulating virus and those caused by vaccine-derived virus as accurately and urgently as possible because the public health response will be quite different. No infant deaths were observed during this outbreak, and no severe adverse events following immunization were seen among infants 6-11 months old who were given MCV as a public health response. Thus, we conclude that introduction of emergent MCV was effective and describing the characteristics of vaccine-associated measles cases during a measles outbreak will be helpful for future outbreak response efforts.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kuba Y, Kyan H, Iha Y, et al. Emergent measles-containing vaccination recommendation for aged 6-11 months and detection of vaccine-associated measles during a large measles outbreak in Okinawa, Japan, in 2018. Vaccine. 2020. PMID: 32037227. doi:10.1016/j.vaccine.2020.01.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。